Stock Analysis on Net
Stock Analysis on Net

Zoetis Inc. (NYSE:ZTS)

This company has been moved to the archive! The financial data has not been updated since May 2, 2024.

Analysis of Liquidity Ratios

Microsoft Excel

Liquidity Ratios (Summary)

Zoetis Inc., liquidity ratios

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Current ratio 3.36 2.37 3.86 3.05 2.63
Quick ratio 1.77 1.51 2.57 2.13 1.67
Cash ratio 1.08 1.13 1.94 1.66 1.07

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).


An analysis of the liquidity position between 2019 and 2023 reveals a consistently strong capacity to meet short-term obligations, characterized by ratios that remained well above standard benchmarks throughout the period. A notable peak in overall liquidity occurred in 2021, followed by a contraction in 2022 and a subsequent partial recovery in 2023.

Current Ratio
The current ratio exhibited an upward trajectory from 2.63 in 2019 to a peak of 3.86 in 2021. A significant decrease to 2.37 was observed in 2022, representing the lowest liquidity level in the five-year period. By the end of 2023, the ratio rebounded to 3.36, indicating a strengthened position of short-term assets relative to current liabilities.
Quick Ratio
Mirroring the trend of the current ratio, the quick ratio rose from 1.67 in 2019 to 2.57 in 2021 before declining to 1.51 in 2022. A recovery to 1.77 occurred in 2023. The consistent variance between the current and quick ratios suggests that inventory constitutes a meaningful portion of the current asset base, although liquidity remains robust even when inventory is excluded from the calculation.
Cash Ratio
The cash ratio increased from 1.07 in 2019 to a maximum of 1.94 in 2021, signifying an exceptionally high level of immediate liquidity. This metric declined to 1.13 in 2022 and remained relatively stable at 1.08 in 2023. Because the cash ratio remained above 1.0 throughout the entire period, it is evident that cash and cash equivalents alone were sufficient to cover all current liabilities at each year-end.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Current Ratio

Zoetis Inc., current ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in millions)
Current assets 6,343 7,506 6,930 6,611 4,748
Current liabilities 1,889 3,167 1,797 2,170 1,806
Liquidity Ratio
Current ratio1 3.36 2.37 3.86 3.05 2.63
Benchmarks
Current Ratio, Competitors2
AbbVie Inc. 0.87 0.96 0.79 — —
Amgen Inc. 1.65 1.41 1.59 — —
Bristol-Myers Squibb Co. 1.43 1.25 1.52 — —
Danaher Corp. 1.68 1.89 1.43 — —
Eli Lilly & Co. 0.94 1.05 1.23 — —
Gilead Sciences Inc. 1.43 1.29 1.27 — —
Johnson & Johnson 1.16 0.99 1.35 — —
Merck & Co. Inc. 1.25 1.47 1.27 — —
Pfizer Inc. 0.91 1.22 1.40 — —
Regeneron Pharmaceuticals Inc. 5.69 5.06 3.56 — —
Thermo Fisher Scientific Inc. 1.75 1.48 1.50 — —
Vertex Pharmaceuticals Inc. 3.99 4.83 4.46 — —
Current Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences 1.27 1.30 1.36 — —
Current Ratio, Industry
Health Care 1.23 1.23 1.31 — —

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
Current ratio = Current assets ÷ Current liabilities
= 6,343 ÷ 1,889 = 3.36

2 Click competitor name to see calculations.


The analysis of liquidity indicators from 2019 to 2023 reveals a consistently strong short-term financial position, characterized by a current ratio that remains significantly above the 1.0 threshold throughout the observed period.

Current Asset Trends
Current assets exhibited a sustained growth trajectory between 2019 and 2022, increasing from US$ 4,748 million to a peak of US$ 7,506 million. This expansion was followed by a contraction in 2023, with current assets declining to US$ 6,343 million.
Current Liability Volatility
Short-term obligations remained relatively stable from 2019 to 2021. A notable spike occurred in 2022, where current liabilities increased to US$ 3,167 million, representing the highest level in the five-year period. This was followed by a sharp reduction to US$ 1,889 million in 2023.
Current Ratio Dynamics
The current ratio trended upward from 2.63 in 2019 to a peak of 3.86 in 2021, indicating an increasing capacity to cover short-term debts. A significant dip to 2.37 was recorded in 2022, directly correlating with the surge in current liabilities. The ratio subsequently recovered to 3.36 in 2023, suggesting a restoration of the liquidity cushion.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Quick Ratio

Zoetis Inc., quick ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in millions)
Cash and cash equivalents 2,041 3,581 3,485 3,604 1,934
Accounts receivable, less allowance for doubtful accounts 1,304 1,215 1,133 1,013 1,086
Total quick assets 3,345 4,796 4,618 4,617 3,020
 
Current liabilities 1,889 3,167 1,797 2,170 1,806
Liquidity Ratio
Quick ratio1 1.77 1.51 2.57 2.13 1.67
Benchmarks
Quick Ratio, Competitors2
AbbVie Inc. 0.63 0.69 0.56 — —
Amgen Inc. 0.99 0.95 1.06 — —
Bristol-Myers Squibb Co. 1.04 0.87 1.20 — —
Danaher Corp. 1.18 1.30 0.89 — —
Eli Lilly & Co. 0.52 0.62 0.79 — —
Gilead Sciences Inc. 1.06 0.99 0.95 — —
Johnson & Johnson 0.82 0.71 1.04 — —
Merck & Co. Inc. 0.68 0.93 0.73 — —
Pfizer Inc. 0.50 0.80 1.00 — —
Regeneron Pharmaceuticals Inc. 4.82 4.16 2.98 — —
Thermo Fisher Scientific Inc. 1.27 1.06 1.00 — —
Vertex Pharmaceuticals Inc. 3.60 4.46 4.04 — —
Quick Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences 0.85 0.91 0.98 — —
Quick Ratio, Industry
Health Care 0.90 0.93 1.00 — —

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
Quick ratio = Total quick assets ÷ Current liabilities
= 3,345 ÷ 1,889 = 1.77

2 Click competitor name to see calculations.


The liquidity position of the entity exhibited significant volatility over the five-year period from 2019 to 2023, characterized by a peak in liquidity during 2021 followed by a sharp contraction and a subsequent partial recovery.

Quick Asset Trends
Total quick assets experienced a substantial increase from US$ 3,020 million in 2019 to a peak of US$ 4,796 million in 2022. This growth was most pronounced between 2019 and 2020, where assets grew by approximately 52.9%. A notable contraction occurred in 2023, with quick assets declining to US$ 3,345 million.
Current Liability Dynamics
Current liabilities fluctuated considerably, moving from US$ 1,806 million in 2019 to a peak of US$ 3,167 million in 2022. The most significant increase occurred between 2021 and 2022, representing a nearly 76% rise in short-term obligations. This trend reversed sharply in 2023, with liabilities falling to US$ 1,889 million.
Quick Ratio Analysis
The quick ratio showed a positive trajectory from 2019 (1.67) through 2021, reaching a maximum of 2.57, which indicates a high capacity to meet immediate obligations. A sharp decline to 1.51 was observed in 2022, coinciding with the surge in current liabilities. By the end of 2023, the ratio recovered to 1.77, suggesting a stabilization of the liquidity profile; this recovery was primarily driven by the substantial reduction in current liabilities, which offset the simultaneous decrease in total quick assets.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Cash Ratio

Zoetis Inc., cash ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019
Selected Financial Data (US$ in millions)
Cash and cash equivalents 2,041 3,581 3,485 3,604 1,934
Total cash assets 2,041 3,581 3,485 3,604 1,934
 
Current liabilities 1,889 3,167 1,797 2,170 1,806
Liquidity Ratio
Cash ratio1 1.08 1.13 1.94 1.66 1.07
Benchmarks
Cash Ratio, Competitors2
AbbVie Inc. 0.34 0.31 0.28 — —
Amgen Inc. 0.60 0.59 0.66 — —
Bristol-Myers Squibb Co. 0.55 0.42 0.78 — —
Danaher Corp. 0.71 0.71 0.32 — —
Eli Lilly & Co. 0.10 0.12 0.25 — —
Gilead Sciences Inc. 0.64 0.57 0.56 — —
Johnson & Johnson 0.50 0.42 0.70 — —
Merck & Co. Inc. 0.28 0.54 0.34 — —
Pfizer Inc. 0.27 0.54 0.73 — —
Regeneron Pharmaceuticals Inc. 3.17 2.46 1.45 — —
Thermo Fisher Scientific Inc. 0.58 0.50 0.33 — —
Vertex Pharmaceuticals Inc. 3.16 3.93 3.51 — —
Cash Ratio, Sector
Pharmaceuticals, Biotechnology & Life Sciences 0.47 0.52 0.58 — —
Cash Ratio, Industry
Health Care 0.50 0.54 0.60 — —

Based on: 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31).

1 2023 Calculation
Cash ratio = Total cash assets ÷ Current liabilities
= 2,041 ÷ 1,889 = 1.08

2 Click competitor name to see calculations.


The cash ratio demonstrates a volatile but consistently strong liquidity position between 2019 and 2023. Throughout the analyzed period, the ratio remained above 1.0, indicating that the company consistently maintained sufficient cash assets to cover its current liabilities in full without relying on the sale of other current assets.

Cash Ratio Trend
The ratio experienced a significant upward trajectory from 2019 to 2021, rising from 1.07 to a peak of 1.94. This indicates a period of aggressive cash accumulation or a strategic increase in liquidity buffers. Following 2021, a downward trend occurred, with the ratio retreating to 1.13 in 2022 and 1.08 in 2023, effectively returning to levels observed at the beginning of the five-year period.
Total Cash Assets
A substantial increase in cash assets was recorded in 2020, rising from 1,934 million to 3,604 million. This elevated cash position remained relatively stable through 2022 before a significant reduction occurred in 2023, where cash assets decreased to 2,041 million.
Current Liabilities
Current liabilities exhibited fluctuation, with a notable spike in 2022 reaching 3,167 million. This peak in liabilities, occurring while cash assets remained steady, contributed to the compression of the cash ratio from 1.94 in 2021 to 1.13 in 2022. By 2023, liabilities decreased significantly to 1,889 million, aligning with the reduction in total cash assets to maintain a ratio just above 1.0.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?